The estimated Net Worth of Eva Renee Barnett is at least $12.3 Million dollars as of 21 August 2024. Ms Barnett owns over 3,768 units of Immunovant Inc stock worth over $9,986,693 and over the last 3 years she sold IMVT stock worth over $2,314,043.
Ms has made over 16 trades of the Immunovant Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently she sold 3,768 units of IMVT stock worth $120,048 on 21 August 2024.
The largest trade she's ever made was selling 29,959 units of Immunovant Inc stock on 7 January 2022 worth over $217,203. On average, Ms trades about 5,437 units every 46 days since 2021. As of 21 August 2024 she still owns at least 343,776 units of Immunovant Inc stock.
You can see the complete history of Ms Barnett stock trades at the bottom of the page.
Eva Renee Barnett M.B.A. is the Chief Financial Officer at Immunovant Inc.
Eva's mailing address filed with the SEC is C/O IMMUNOVANT, INC., 320 W 37TH STREET, 6TH FLOOR, NEW YORK, NY, 10018.
Over the last 5 years, insiders at Immunovant Inc have traded over $21,959,710 worth of Immunovant Inc stock and bought 3,433,213 units worth $88,718,319 . The most active insiders traders include Sciences Ltd. Roivant, Peter Salzmann, and Julia G. Butchko. On average, Immunovant Inc executives and independent directors trade stock every 14 days with the average trade being worth of $1,150,148. The most recent stock trade was executed by Mark S. Levine on 21 August 2024, trading 3,295 units of IMVT stock currently worth $104,979.
immunovant, inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. it develops imvt-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in phase iia clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of phase ii clinical trials for the treatment of warm autoimmune hemolytic anemia. the company is headquartered in new york, new york. immunovant, inc. is a subsidiary of roivant sciences ltd.
Immunovant Inc executives and other stock owners filed with the SEC include: